Search results
Showing 1701 to 1750 of 2989 results for all
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (AMR2)
Evidence-based recommendations on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.
Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.
Burosumab for treating X-linked hypophosphataemia in adults (TA993)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]
In development Reference number: GID-TA11096 Expected publication date: TBC
Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making
Sternal Talon for sternal closure in cardiothoracic surgery (MIB88)
NICE has developed a medtech innovation briefing (MIB) on the Sternal Talon for sternal closure in cardiothoracic surgery .
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and non-inflammatory bowel diseases (such as irritable bowel syndrome).
Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (HTG607)
Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.
NICE has developed a medtech innovation briefing (MIB) on The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease .
Xpert Carba-R to identify people carrying carbapenemase-producing organisms (MIB52)
NICE has developed a medtech innovation briefing (MIB) on the Xpert Carba-R to identify people carrying carbapenemase-producing organisms
ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)
NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot
BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume (MIB50)
NICE has developed a medtech innovation briefing (MIB) on the BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume
Digital technologies to support self-management of COPD: early value assessment (HTG736)
Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.
NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery .
Lumella point-of-care test for assessing pre-eclampsia risk (MIB287)
NICE has developed a medtech innovation briefing (MIB) on Lumella point-of-care test for assessing pre-eclampsia risk .
CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)
NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .
NICE has developed a medtech innovation briefing (MIB) on URO17 for detecting bladder cancer .
Icare rebound tonometer to measure intraocular pressure (MIB57)
NICE has developed a medtech innovation briefing (MIB) on the Icare rebound tonometer to measure intraocular pressure
ColonFlag for identifying people at risk of colorectal cancer (MIB142)
NICE has developed a medtech innovation briefing (MIB) on ColonFlag for identifying people at risk of colorectal cancer .
Find out what guidance is being considered for development
Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.
Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)
Evidence-based recommendations on vedolizumab (Entyvio) for treating moderate to severe ulcerative colitis in adults.
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet clinically indicated.
Ocrelizumab for treating primary progressive multiple sclerosis (TA585)
Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis in adults.
Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)
Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults.
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.
VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (HTG362)
Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy.
Insertion of a collagen plug to close an abdominal wall enterocutaneous fistula (HTG359)
Evidence-based recommendations on insertion of a collagen plug to close an abdominal wall enterocutaneous fistula. This involves inserting a collagen plug into the fistula to seal off where it joins the bowel.
Evidence-based recommendations on velmanase alfa (Lamzede) for treating alpha-mannosidosis in people under 18 years and in people who turn 18 while on treatment.
Inotersen for treating hereditary transthyretin amyloidosis (HST9)
Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis.
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
Evidence-based recommendations on bevacizumab (Avastin) and cetuximab (Erbitux) for treating metastatic colorectal cancer in adults.
Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance.
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia (HTG578)
Evidence-based recommendations on UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia.
Service user experience in adult mental health services (QS14)
This quality standard covers improving the experience of people using adult NHS mental health services. It describes high-quality care in priority areas for improvement.
View quality statements for QS14Show all sections
Sections for QS14
- Quality statements
- Quality statement 1: Empathy, dignity and respect
- Quality statement 2: Decision making
- Quality statement 3: Involvement to improve services
- Quality statement 4: Contacts for ongoing care
- Quality statement 5: Access to services
- Quality statement 6: Joint care planning
- Quality statement 7: Inpatient contact with staff
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
NICE has developed a medtech innovation briefing (MIB) on Hemosep for cell salvage .
the menopause is called anastrozole. However, this may not be suitable for all women; for example, women who have severe osteoporosis....
Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)
Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatments (TA1091)
Evidence-based recommendations on tarlatamab (IMDYLLTRA) for treating extensive-stage small-cell lung cancer after 2 or more treatments in adults.
Show all sections
NICE has developed a medtech innovation briefing (MIB) on 24/7 EEG SubQ for epilepsy .
Mapping NICE guidelines to the CQC's single assessment framework
This NICE resource is intended to demonstrate how our guidance can be used in the Care Quality Commission (CQC) assessment process.
Partner with NICE in our research work
Jobs in digital at NICE. Come and join us!
Our Medical Technologies Evaluation Programme (MTEP) evaluates new HealthTech.
Evidence-based recommendations on abemaciclib (Verzenios) with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence in adults.
Preventing suicide in community and custodial settings (NG105)
This guideline covers ways to reduce suicide and help people bereaved or affected by suicides. It aims to:
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]
In development Reference number: GID-TA10832 Expected publication date: TBC
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Awaiting development Reference number: GID-TA11215 Expected publication date: 07 May 2026